Alnylam Pharmaceuticals
ALNY
#378
Rank
A$91.11 B
Marketcap
A$689.70
Share price
-1.55%
Change (1 day)
72.25%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2025 (TTM): A$0.18 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are A$3.21 Billion. In 2024 the company made an earning of -A$0.36 Billion, an increase over its 2023 earnings that were of -A$0.48 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) A$0.18 B-151.38%
2024 -A$0.36 Billion-24.59%
2023 -A$0.48 Billion-67.84%
2022 -A$1.47 Billion36.93%
2021 -A$1.07 Billion-8.04%
2020 -A$1.17 Billion-15.66%
2019 -A$1.38 Billion12.23%
2018 -A$1.23 Billion62.91%
2017 -A$0.76 Billion17.78%
2016 -A$0.64 Billion43.44%
2015 -A$0.45 Billion60.69%
2014 -A$0.28 Billion98.2%
2013 -A$0.14 Billion
2011 -A$82.53 Million27.48%
2010 -A$64.74 Million-10.92%
2009 -A$72.68 Million95.77%
2008 -A$37.13 Million
2006 -A$59.47 Million-9.13%
2005 -A$65.45 Million34.74%
2004 -A$48.58 Million36.79%
2003 -A$35.51 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Arrowhead Pharmaceuticals
ARWR
-A$0.12 Billion-157.61%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
A$7.74 B 3,848.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-A$0.38 Billion-293.52%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-A$0.25 Billion-222.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-A$71.41 Million-136.39%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
A$24.71 B 12,499.18%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
A$13.70 B 6,883.12%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
A$2.66 B 1,259.75%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel